GLP-2 TIRZExplore study findings
What a head-to-head trial taught researchers about glucose categories
3 numbered sourcesSource years 2022–2026
Peptides are short chains of amino acids joined by peptide bonds. Some can mimic hormones that influence blood sugar after eating. Tirzepatide is a peptide that activates GIP and GLP-1 receptors. It appears under “GLP-2 TIRZ” in the catalog, a name distinct from its receptor targets. In a 2026 secondary analysis of SURMOUNT-5, investigators examined blood sugar measures in participants who began a weight-management trial with prediabetes. [1, 2, 3]
The original trial randomly assigned adults with obesity or overweight and a related complication to tirzepatide or semaglutide. It excluded type 2 diabetes. Its main comparison concerned weight change at 72 weeks. The later analysis focused on participants whose starting laboratory values met the study’s criteria for prediabetes. Prediabetes is a category defined by elevated glucose measurements below the criteria for diabetes. A later measurement can move a person into the study’s normal range. [1, 2]
The researchers used two measures to classify whether participants had reached normal glucose values at week 72. Fasting glucose reflects the concentration in a blood sample at the time of testing. HbA1c reflects average exposure over a longer period. The analysis reported more participants meeting its normal glucose criteria with tirzepatide than with semaglutide. It also reported a larger reduction in an estimate of insulin resistance for the tirzepatide group. The insulin resistance measure was calculated from fasting values rather than measured directly in a separate physiological test. [1]
The result is an analysis of a subset of participants in a randomized trial. Starting in the prediabetes subgroup makes the question clear and reduces the number of participants available for analysis. The authors also made statistical assumptions for missing week-72 measurements. The comparisons help show how the treatments differed on these measures under the study conditions. Classification at the end of follow-up does not indicate whether a person would stay in that category indefinitely or after stopping treatment. [1]
The original study’s weight result and the later paper’s glucose findings describe different outcomes from the same underlying trial. They should be read together to understand who took part and what was tested. The later analysis is additional evidence about a defined glucose outcome, not a new independent trial. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
